上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
GNE-274
GNE-274 是 ER 降解剂 GDC-0927 的结构类似物,是一种非降解剂。GNE-274 在乳腺癌细胞系中不诱导 ER 的转换,作为 ER 的部分激动剂 (partial ER agonist) 发挥作用。GNE-274 增加了ER-DNA 结合位点的的染色质可进入性,而 GDC-0927 则没有。GNE-274 是一种有效的 ER 配体结合域 (LBD) 抑制剂。GNE-274 可用于癌症研究。
GNE-274 Chemical Structure
CAS No. : 2369048-69-9
规格 | 是否有货 | ||
---|---|---|---|
100 mg | 询价 | ||
250 mg | 询价 | ||
500 mg | 询价 |
* Please select Quantity before adding items.
生物活性 |
GNE-274 is a non-degrader that is structurally related to GDC-0927 (ER degrader). GNE-274 does not induce ER turnover and functions as a partial ER agonist in breast cancer cell lines. GNE-274 increase chromatin accessibility at ER-DNA binding sites, while GDC-0927 do not. GNE-274 is a potent inhibitor of ER-ligand binding domain (LBD). GNE-274 can be used for cancer research[1][2]. |
||||||||
---|---|---|---|---|---|---|---|---|---|
体外研究 (In Vitro) |
GNE-274 (0.1 nM-1000 nM; 4 hours) fails to trigger increased ER turnover in MCF7, MD-134, HCC1500 and CAMA cells[1].GNE-274 (1-1000 nM; 7-10 days) potently inhibits cellular proliferation, exhibiting greater potency than fulvestrant, 4-OHT, AZD9496, and GDC-0810 in E2-stimulated ER+ breast cancer cell lines[1].In transposaseaccessible chromatin sequencing (ATAC-seq) assay, GNE-274 increase chromatin accessibility at ER-DNA binding sites, it significantly alters chromatin accessibility at 594 sites. But GDC-0927 has considerably less impact on chromatin accessibility[1]. Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay[1]
|
||||||||
分子量 |
457.56 |
||||||||
Formula |
C29H31NO4 |
||||||||
CAS 号 |
2369048-69-9 |
||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||
储存方式 |
Please store the product under the recommended conditions in the Certificate of Analysis. |
||||||||
参考文献 |
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务